Pharmacy Times August 7, 2024
Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.
The commonalities between type 2 diabetes (T2D) and neurodegenerative disorders have gained increasing attention in terms of treatment opportunities, explained Nigel H. Greig, PhD, a senior investigator in the Translational Gerontology Branch at the National Institute of Health, during a presentation at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia, Pennsylvania. Notably, commonalities in cell death pathways between these conditions suggest that treatments effective in one may also benefit the other, according to Greig.1
Among the promising therapeutic candidates are glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have shown potential in reducing the risk of...
Today's Sponsors
Today's Sponsor